Indivior (NASDAQ:INDV – Get Free Report) is expected to be announcing its Q3 2026 results before the market opens on Thursday, October 29th. Analysts expect the company to post earnings of $1.06 per share and revenue of $329.35 million for the quarter. Parties may review the information on the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Thursday, October 29, 2026 at 9:00 AM ET.
Indivior (NASDAQ:INDV – Get Free Report) last posted its quarterly earnings results on Tuesday, June 30th. The company reported $5.75 EPS for the quarter. Indivior had a negative return on equity of 283.11% and a net margin of 26.65%. The business had revenue of $343.00 million for the quarter. On average, analysts expect Indivior to post $3.66 EPS for the current fiscal year and $3.83 EPS for the next fiscal year.
Indivior Stock Up 0.3%
Shares of Indivior stock opened at $34.56 on Tuesday. The stock’s 50-day simple moving average is $35.59 and its 200-day simple moving average is $35.63. Indivior has a 52 week low of $24.28 and a 52 week high of $42.81. The company has a market capitalization of $4.08 billion, a price-to-earnings ratio of 9.44 and a beta of 0.87.
Indivior Announces Dividend
The firm also recently announced a special dividend, which will be paid on Friday, November 6th. Investors of record on Friday, October 30th will be given a dividend of $8.13 per share.
Insider Buying and Selling
In related news, CAO Woodrow D. Anderson acquired 1,500 shares of the company’s stock in a transaction on Thursday, August 27th. The stock was acquired at an average price of $35.69 per share, with a total value of $53,535.00. Following the acquisition, the chief accounting officer directly owned 27,638 shares of the company’s stock, valued at approximately $986,400.22. This trade represents a 5.74% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through this link. 0.74% of the stock is currently owned by insiders.
Wall Street Analysts Forecast Growth
Several analysts recently issued reports on INDV shares. Barclays decreased their target price on Indivior from $46.00 to $43.00 and set an “overweight” rating on the stock in a research note on Wednesday, August 5th. Weiss Ratings lowered shares of Indivior from a “buy (b-)” rating to a “hold (c+)” rating in a report on Thursday, September 24th. Craig Hallum reaffirmed a “buy” rating and set a $53.00 price objective on shares of Indivior in a report on Tuesday, August 4th. Finally, Zacks Research upgraded shares of Indivior from a “hold” rating to a “strong-buy” rating in a research report on Friday, October 2nd. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of $45.17.
Read Our Latest Stock Analysis on Indivior
About Indivior
Indivior PLC (NASDAQ:INDV) is a global pharmaceutical company focused on developing and commercializing medicines for substance use disorders and serious mental health conditions. Its portfolio is centered on treatments for opioid use disorder, opioid overdose, and related medical needs.
The company’s principal products include Sublocade, an extended-release buprenorphine injection for opioid use disorder; Suboxone, a buprenorphine and naloxone treatment available in film and other formulations; and Opvee, a nalmefene nasal spray intended for the emergency treatment of known or suspected opioid overdose.
Featured Stories
- Five stocks we like better than Indivior
- Comfort Systems Earnings: AI Slowdown or More Growth Ahead?
- Bristol Myers Squibb’s Cancer Breakthrough Could Have Implications Beyond Its Own Stock
- 5 Beaten-Down Growth Stocks Trading Like Value Plays as Cash Chases Mega-Caps
- Anthropic’s IPO Filing Reveals a Massive Opportunity for AI Infrastructure Giants
Receive News & Ratings for Indivior Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Indivior and related companies with MarketBeat.com's FREE daily email newsletter.
